In this study, a budget impact analysis of changing reimbursement criteria for osteoporosis drug therapy was conducted to help rational improvements on the current reimbursement criteria which has been criticized for years by the professional society.

This study considered the impact of the reimbursement expansion in both increased medical expenditure and reduced osteoporotic fracture related expenditure from preventing osteoporosis progression into a serious stage.